Celgene Corporation (CELG) Shares Sold by Prentiss Smith & Co. Inc.

Prentiss Smith & Co. Inc. decreased its stake in shares of Celgene Corporation (NASDAQ:CELG) by 7.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,480 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Celgene Corporation comprises 0.7% of Prentiss Smith & Co. Inc.’s portfolio, making the stock its 28th largest holding. Prentiss Smith & Co. Inc.’s holdings in Celgene Corporation were worth $1,361,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in Celgene Corporation during the first quarter valued at approximately $118,000. Oakworth Capital Inc. lifted its position in Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 412 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the period. Independent Portfolio Consultants Inc. lifted its position in Celgene Corporation by 209.4% during the first quarter. Independent Portfolio Consultants Inc. now owns 1,541 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 1,043 shares during the period. Finally, Schmidt P J Investment Management Inc. bought a new position in Celgene Corporation during the first quarter valued at approximately $201,000. Institutional investors own 79.43% of the company’s stock.

In related news, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the sale, the insider now owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold 267,476 shares of company stock valued at $35,812,841 in the last ninety days. Insiders own 0.95% of the company’s stock.

Several research firms have weighed in on CELG. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price target (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. BMO Capital Markets reiterated an “outperform” rating and issued a $160.00 price target (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $149.34.

Celgene Corporation (NASDAQ CELG) traded up 1.02% during midday trading on Friday, hitting $142.04. 5,983,997 shares of the stock traded hands. The stock has a 50-day moving average of $134.97 and a 200 day moving average of $127.46. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.69. The firm has a market cap of $111.12 billion, a PE ratio of 43.99 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the firm earned $1.44 earnings per share. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts forecast that Celgene Corporation will post $7.33 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Sold by Prentiss Smith & Co. Inc.” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://transcriptdaily.com/2017/09/17/celgene-corporation-celg-shares-sold-by-prentiss-smith-co-inc.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply